Login to Your Account

BMS, AstraZeneca Join Forces in $7B Combo Deal for Amylin

By Catherine Shaffer
Staff Writer

Thursday, July 5, 2012
Bristol Myers Squibb Co., of New York, will realize operating synergies and tax benefits in addition to gaining access to Amylin Pharmaceuticals Inc.'s GLP-1 franchise, executives said in a Monday morning conference call regarding the pharma giant's acquisition of San Diego-based Amylin and partnership agreement with AstraZeneca plc.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription